AstraZeneca (AZN) Moves to Session Highs; Onglyza Receives Positive FDA Panel Vote on Heart Risk
Get Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) is continuing to session highs Tuesday after it was reported that the company's diabetes drug received a positive FDA panel vote.
The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 13 - 1 that Onglyza has an acceptable heart failure risk. The panel also said the drug's label should be changed to add information reflecting the risk.
Committee members were only mildly concerned about an increased risk of death from all causes.
Shares of AstraZeneca are up 3.4 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
- Biogen (BIIB) Receives Positive CHMP Opinion for TOFIDENCE
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!